Key result
Treatment with prednisolone and mizoribine successfully improved cardiac function, increasing ejection fraction from 31% to 48%, in a patient with chronic lupus myocarditis.
Why the study?
Does treatment with prednisolone and mizoribine improve cardiac function in a patient with chronic lupus myocarditis?
Case Report (n=1)
No
Does treatment with prednisolone and mizoribine improve cardiac function in a patient with chronic lupus myocarditis?
Prednisolone combined with mizoribine may be an effective treatment strategy for chronic lupus myocarditis.
Answers are grounded in this paper and cite their sources.
May support prednisolone-mizoribine in chronic lupus myocarditis; hypothesis-generating and requires prospective validation.
A 36-year-old female patient who was diagnosed with chronic myocarditis as an initial manifestation of systemic lupus erythematosus (SLE) was admitted to our hospital. At her third occurrence of heart failure, we performed an endomyocardial biopsy and proved chronic myocarditis with SLE. Subsequently, she was treated with prednisolone and the immunosuppressive agent mizoribine (MZR), and her cardiac function improved. We describe for the first time treatment with MZR for chronic cardiac involvement of SLE.
No takes yet. Share an insight, caveat, or question.
Akazawa et al. (2010) conducted a case report in Chronic lupus myocarditis (n=1). Prednisolone and mizoribine was evaluated on Improvement in cardiac function (ejection fraction). Treatment with prednisolone and mizoribine successfully improved cardiac function, increasing ejection fraction from 31% to 48%, in a patient with chronic lupus myocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: